FDA clears PETNet for commercial 18F FDG sales

Siemens subsidiary PETNet has been granted FDA approval for its Abbreviated New Drug Application (ANDA) for fludeoxyglucose F 18 (18F FDG) injection.

The approval readies PetNet to manufacture and distribute 18F FDG for PET imaging from one of the company’s 54 global production and distribution sites. PetNet is the first company to receive FDA approval for commercial sale of the biomarker, the Knoxville, Tenn.-based company said.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.